◎ Sugi Atlas

Atlas / Drug / Naproxen

Naproxen

drug
On this page

Also known as Arthrosin 250Arthrosin 250 ecArthrosin 500Arthrosin 500 ecCondrotecEc-naprosynFeminax ultraGrenoxalKenosynLaraflexNapratec opNaprosynNaprosyn 375Naprosyn ecNAPROXEN COMPONENT OF PN400Naproxen component of vimovoNaproxeneNaproxenoNSC-750183

Summary

Naproxen (CHEMBL154) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC G02CC02) targeting PTGS1 and PTGS2; indicated across 39 conditions including rheumatoid arthritis and vaginitis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G02CC02 (+2 more)
  • Targets: 2 (PTGS1, PTGS2)
  • Indications: 39 conditions
  • Clinical trials: 210
  • Chemistry: 230.26 Da · C14H14O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL154
NameNaproxen
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID156391
ChEBICHEBI:7476
ATCG02CC02, M01AE02, M02AA12
Molecular formulaC14H14O3
Molecular weight230.26
InChIKeyCMWTZPSULFXXJA-VIFPVBQESA-N

SMILES: C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O

IUPAC name: (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid

ChEBI definition: A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, antipyretic, cyclooxygenase 2 inhibitor, cyclooxygenase 1 inhibitor, non-narcotic analgesic, gout suppressant, drug allergen.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: Arthrosin 250, Arthrosin 250 ec, Arthrosin 500, Arthrosin 500 ec, Condrotec, Ec-naprosyn, Feminax ultra, Grenoxal, Kenosyn, Laraflex, Napratec op, Naprosyn

Parent form; salt/anhydrous children: CHEMBL1200806

Patent coverage: 37,209 distinct patent families (136,434 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 135,777 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition5.490%P23219
PTGS2COX-2Inhibition5.60%P35354

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Solute carrier family 22 member 6, Solute carrier family 22 member 6, Thyrotropin receptor, Cyclooxygenase, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 1, Androgen receptor, Polyunsaturated fatty acid 5-lipoxygenase.

Bioactivity

ChEMBL activities: 33 potent at pChembl ≥ 5 of 55 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P353557.22IC5060nMCHEMBL_ACT_842101
P059797.21IC5061nMCHEMBL_ACT_19431087
PTGS17.18AC5065.9nMCHEMBL_ACT_25205385
PTGS16.8AC50157nMCHEMBL_ACT_25206316
P059796.75IC50180nMCHEMBL_ACT_12635508
AKR1C36.75IC50180nMCHEMBL_ACT_19431045
AKR1C36.75IC50180nMCHEMBL_ACT_28817540
P059796.75IC50180nMCHEMBL_ACT_5314336
PTGS16.68IC50211nMCHEMBL_ACT_7731120
PTGS16.46IC50350nMCHEMBL_ACT_1122319
AKR1C36.32IC50480nMCHEMBL_ACT_1654355
TSHR6.1Potency794.3nMCHEMBL_ACT_3914722
TSHR6.1Potency794.3nMCHEMBL_ACT_4715173
PTGS26.05IC50900nMCHEMBL_ACT_19431095
AKR1C35.96IC501100nMCHEMBL_ACT_12105578
P153045.92IC501200nMCHEMBL_ACT_2370404
AKR1C25.9IC501260nMCHEMBL_ACT_19431059
AKR1C25.9IC501260nMCHEMBL_ACT_28817543
O359565.7Ki2000nMCHEMBL_ACT_11002856
PTGS25.67AC502161nMCHEMBL_ACT_25166231
PTGS25.62IC502390nMCHEMBL_ACT_24748090
PTGS25.6IC502500nMCHEMBL_ACT_909385
P059795.57IC502700nMCHEMBL_ACT_553884
PTGS15.5IC503200nMCHEMBL_ACT_909384
P792085.47IC503360nMCHEMBL_ACT_18666384
P0DTD15.46IC503450nMCHEMBL_ACT_25516577
P059795.34IC504600nMCHEMBL_ACT_29210026
Q639215.27AC505400nMCHEMBL_ACT_25173858
SLC22A65.24IC505800nMCHEMBL_ACT_11001775
PTGS15.06IC508650nMCHEMBL_ACT_24748086

Target pathways

Aggregated over 2 target gene(s): PTGS1, PTGS2.

Top Reactome pathways

9 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

39 indications (22 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rheumatoid arthritis4MONDO:0008383EFO:0000685
vaginitis4MONDO:0002234EFO:0005757
ankylosing spondylitis4MONDO:0005306EFO:0003898
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
rheumatic disorder4MONDO:0005554EFO:0005755
gout4MONDO:0005393EFO:0004274
gastric ulcer4MONDO:0001126EFO:0009454
arthritic joint disease4MONDO:0005578EFO:0005856
common cold4MONDO:0005709EFO:0007214
bursitis4MONDO:0002471MONDO:0002471
spondylitis4MONDO:0003937MONDO:0003937
disease of the tendon4MONDO:0100010MONDO:0004857
osteoarthritis4MONDO:0005178MONDO:0005178
osteoarthritis, knee3MONDO:0005416EFO:0004616
osteoarthritis, hip3MONDO:0006629EFO:1000786
peptic ulcer disease3MONDO:0004247HP:0004398
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
migraine disorder3MONDO:0005277MONDO:0005277
multiple sclerosis3MONDO:0005301MONDO:0005301
duodenal ulcer2MONDO:0005412EFO:0004607
prostate adenocarcinoma2MONDO:0005082EFO:0000673
neuralgia2MONDO:0021667EFO:0005762
breast neoplasm2MONDO:0021100MONDO:0007254
injury2MONDO:0021178EFO:0000546
Alzheimer disease2MONDO:0004975MONDO:0004975

14 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 210.

Phase distribution

PhaseTrials
PHASE453
PHASE146
PHASE340
PHASE236
Not specified25
EARLY_PHASE14
PHASE2/PHASE33
PHASE1/PHASE23

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04875702PHASE4RECRUITINGTreat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT05430230PHASE4ACTIVE_NOT_RECRUITINGStudy of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
NCT05851976PHASE4RECRUITINGDuloxetine for LBP
NCT06484192PHASE4ENROLLING_BY_INVITATIONPain Control After Lumbar Spine Fusion
NCT06562816PHASE4RECRUITINGComparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain
NCT06861920PHASE4RECRUITINGNSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)
NCT00137033PHASE4COMPLETEDCelebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
NCT00222976PHASE4COMPLETEDOral vs Rectal Admin of Naproxen for Post-Vag Perineal Pain Control
NCT00261586PHASE4COMPLETEDA Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach
NCT00346216PHASE4COMPLETEDProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
NCT00410995PHASE4TERMINATEDEffects of Naproxen on Physical Performance
NCT00449787PHASE4COMPLETEDComparing Naproxen to Sumatriptan for Emergency Headache Patients
NCT00586365PHASE4WITHDRAWNNaproxen for the Prevention of HO After Complex Elbow Trauma
NCT00615875PHASE4UNKNOWNNaproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial
NCT00643799PHASE4COMPLETEDSafety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis
NCT00650455PHASE4COMPLETEDEfficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
NCT00778193PHASE4COMPLETEDEffect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers
NCT00792636PHASE4COMPLETEDA Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
NCT00807846PHASE4COMPLETEDA Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects
NCT00826462PHASE4COMPLETEDTreatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis
NCT01071317PHASE4COMPLETEDTrial of Comprehensive Migraine Intervention
NCT01165307PHASE4COMPLETEDMedical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
NCT01525043PHASE4COMPLETEDStudy to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow
NCT01587274PHASE4COMPLETEDA Randomized Study of Three Medication Regimens for Acute Low Back Pain
NCT01951105PHASE4COMPLETEDEffect of L-dopa In Subacute Back Pain Population
NCT01994226PHASE4COMPLETEDColchicine Or Naproxen Treatment for ACute gouT
NCT02013427PHASE4COMPLETEDPlacebo In Chronic Back Pain - Double-Blind Randomized Control Trial
NCT02252614PHASE4UNKNOWNEfficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain
NCT02255955PHASE4UNKNOWNPostoperative Analgesia in Laminectomy
NCT02281968PHASE4WITHDRAWNNSAIDs for Pain After Ankle Fracture Surgery
NCT02355236PHASE4UNKNOWNGastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis
NCT02451748PHASE4COMPLETEDIL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02500641PHASE4COMPLETEDIntensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
NCT02501564PHASE4COMPLETEDEvaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
NCT02519231PHASE4COMPLETEDCopper IUD Treatment Observation Study
NCT02604550PHASE4COMPLETEDAnterior Cruciate Ligament Pain Study
NCT02665286PHASE4COMPLETEDOrphenadrine and Methocarbamol for LBP
NCT02667730PHASE4COMPLETEDCorrelation Between Acute Analgesia and Long-Term Function Following Ankle Injuries
NCT02689024PHASE4TERMINATEDDelirium in Elderly Patients With Trauma of the Hip
NCT02986334PHASE4COMPLETEDPlacebo In Chronic Back Pain (Phase 2)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

407 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2
MAVACOXIBChEMBLPhase 2PTGS1, PTGS2
MIROPROFENChEMBLPhase 2PTGS1, PTGS2
NIFLUMIC ACIDChEMBLPhase 2PTGS1, PTGS2
PHENOTHIAZINEChEMBLPhase 2PTGS1, PTGS2
PIRMAGRELChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot